BACKGROUND: For patients with unresectable intrahepatic cholangiocarcinoma (ICC), treatment options are limited and survival is poor. This study summarizes the long-term outcome of two previously reported clinical trials using hepatic arterial infusion (HAI) with floxuridine and dexamethasone (with or without bevacizumab) in advanced ICC. METHODS: Prospectively collected clinicopathologic and survival data were retrospectively reviewed. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST). Pre-HAI dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) images were reviewed, and tumor perfusion data correlated with outcome. RESULTS: Forty-four patients were analyzed (floxuridine, 26; floxuridine/bevacizumab, 18). At a median follow-up of 29.3 months, 41 patients had died of disease. Partial response by RECIST was observed in 48 %, and 50 % had stable disease. Three patients underwent resection after response, and 82 % received additional HAI after removal from the trials. Median survival was similar in both trials (floxuridine 29.3 months vs. floxuridine/bevacizumab 28.5 months; p = 0.96). Ten (23 %) patients survived ≥3 years, including 5 (11 %) who survived ≥5 years. Tumor perfusion measured on pre-treatment DCE-MRI [area under the gadolinium concentration curve at 90 and 180 s (AUC90 and AUC180, respectively)] was significantly higher in ≥3-year survivors and was the only factor that distinguished this group from <3-year survivors (mean AUC90 22.6 vs. 15.9 mM s, p = 0.025, and mean AUC180 48.9 vs. 32.3 mM s, p = 0.003, respectively). Median hepatic progression-free survival was longer in ≥3-year survivors (12.9 vs. 9.3 months, respectively; p = 0.008). CONCLUSIONS: HAI chemotherapy can result in prolonged survival in unresectable ICC. Pre-HAI DCE-MRI may predict treatment outcome.
BACKGROUND: For patients with unresectable intrahepatic cholangiocarcinoma (ICC), treatment options are limited and survival is poor. This study summarizes the long-term outcome of two previously reported clinical trials using hepatic arterial infusion (HAI) with floxuridine and dexamethasone (with or without bevacizumab) in advanced ICC. METHODS: Prospectively collected clinicopathologic and survival data were retrospectively reviewed. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST). Pre-HAI dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) images were reviewed, and tumor perfusion data correlated with outcome. RESULTS: Forty-four patients were analyzed (floxuridine, 26; floxuridine/bevacizumab, 18). At a median follow-up of 29.3 months, 41 patients had died of disease. Partial response by RECIST was observed in 48 %, and 50 % had stable disease. Three patients underwent resection after response, and 82 % received additional HAI after removal from the trials. Median survival was similar in both trials (floxuridine 29.3 months vs. floxuridine/bevacizumab 28.5 months; p = 0.96). Ten (23 %) patients survived ≥3 years, including 5 (11 %) who survived ≥5 years. Tumor perfusion measured on pre-treatment DCE-MRI [area under the gadolinium concentration curve at 90 and 180 s (AUC90 and AUC180, respectively)] was significantly higher in ≥3-year survivors and was the only factor that distinguished this group from <3-year survivors (mean AUC90 22.6 vs. 15.9 mM s, p = 0.025, and mean AUC180 48.9 vs. 32.3 mM s, p = 0.003, respectively). Median hepatic progression-free survival was longer in ≥3-year survivors (12.9 vs. 9.3 months, respectively; p = 0.008). CONCLUSIONS: HAI chemotherapy can result in prolonged survival in unresectable ICC. Pre-HAI DCE-MRI may predict treatment outcome.
Authors: A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David H Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David R Spriggs; William P Tew Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: W R Jarnagin; L H Schwartz; D H Gultekin; M Gönen; D Haviland; J Shia; M D'Angelica; Y Fong; R DeMatteo; A Tse; L H Blumgart; N Kemeny Journal: Ann Oncol Date: 2009-06-02 Impact factor: 32.976
Authors: Hyun Young Woo; Si Hyun Bae; Jun Yong Park; Kwang Hyub Han; Ho Jong Chun; Byung Gil Choi; Hyeon U Im; Jong Young Choi; Seung Kew Yoon; Jae Youn Cheong; Sung Won Cho; Byoung Kuk Jang; Jae Seok Hwang; Sang Gyune Kim; Young Seok Kim; Yeon Seok Seo; Hyung Joon Yim; Soon Ho Um Journal: Cancer Chemother Pharmacol Date: 2009-09-18 Impact factor: 3.333
Authors: Chaan S Ng; David L Raunig; Edward F Jackson; Edward A Ashton; Frederick Kelcz; Kevin B Kim; Razelle Kurzrock; Teresa M McShane Journal: AJR Am J Roentgenol Date: 2010-02 Impact factor: 3.959
Authors: G V Kornek; B Schuell; F Laengle; T Gruenberger; M Penz; K Karall; D Depisch; F Lang; W Scheithauer Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: Nancy E Kemeny; Fidel D Huitzil Melendez; Marinela Capanu; Philip B Paty; Yuman Fong; Lawrence H Schwartz; William R Jarnagin; Dina Patel; Michael D'Angelica Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Emily A Aherne; Linda M Pak; Debra A Goldman; Mithat Gonen; William R Jarnagin; Amber L Simpson; Richard K Do Journal: Abdom Radiol (NY) Date: 2018-10
Authors: Katja Pinker; Fuki Shitano; Evis Sala; Richard K Do; Robert J Young; Andreas G Wibmer; Hedvig Hricak; Elizabeth J Sutton; Elizabeth A Morris Journal: J Magn Reson Imaging Date: 2017-11-02 Impact factor: 4.813
Authors: Alexandre Doussot; Mithat Gonen; Jimme K Wiggers; Bas Groot-Koerkamp; Ronald P DeMatteo; David Fuks; Peter J Allen; Olivier Farges; T Peter Kingham; Jean Marc Regimbeau; Michael I D'Angelica; Daniel Azoulay; William R Jarnagin Journal: J Am Coll Surg Date: 2016-06-11 Impact factor: 6.113
Authors: T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica Journal: Curr Probl Surg Date: 2020-06-30 Impact factor: 1.909
Authors: Eran Sadot; Amber L Simpson; Richard K G Do; Mithat Gonen; Jinru Shia; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; William R Jarnagin Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240